- 1Department of Thoracic Surgery, Tangdu Hospital, The Air Force Military Medical University, Xi’an, China
- 2The Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Health Statistics, School of Public Health, The Air Force Military Medical University, Xi’an, China
A Corrigendum on
Dynamin 3 inhibits the proliferation of non-small-cell lung cancer cells by suppressing c-MET–GBR2–STAT3 complex formation
by Lu Q, Ni Y, Wang W, Wang L, Jiang T and Shang L (2021). Front. Cell Dev. Biol. 9:641403. doi: 10.3389/fcell.2021.641403
In the published article, there was an error in Figure 6B as published. The wrong bar chart for SNAIL mRNA was erroneously inserted for Figure 6B. The corrected Figure 6 and its caption appear below.

Figure 6. The c-MET inhibitor has tumor suppressive effects on DNM3-depleted lung cancer cells and tumors. (A–D) H1299 cells with or without stable DNM3 knockdown were treated with 10 µM crizotinib (CZT) for 24 h. (A) Western blot assay of the expression of the indicated proteins. (B) RT-qPCR assay of the mRNA levels of CCND1 and SNAI1. (C) Brdu assay of cell proliferation. (D) Transwell assay of the migration of the cells. (E) Nude mice xenografted with H1299 cells with or without stable DNM3 knockdown were treated with CZT (35 mg/kg per day for 12 days) by oral gavage (n = 5 for each group). The tumor growth was monitored. (F) Nude mice (n = 5 for each group) injected via the tail vein with H1299 cells with or without stable DNM3 knockdown were treated with CZT (35 mg/kg per day for 12 days) by oral gavage (n = 5 for each group). The number of metastatic tumor nodules in the lung was counted. Experiments for (A–D) were repeated 3 times. *p < 0.05; **p < 0.01; ***p < 0.001.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: dynamin 3, lung cancer, non-small-cell lung cancer, growth factor receptor-bound protein 2, antitumor effect
Citation: Lu Q, Ni Y, Wang W, Wang L, Jiang T and Shang L (2025) Corrigendum: Dynamin 3 inhibits the proliferation of non-small-cell lung cancer cells by suppressing c-MET–GBR2–STAT3 complex formation. Front. Cell Dev. Biol. 13:1566930. doi: 10.3389/fcell.2025.1566930
Received: 07 February 2025; Accepted: 28 April 2025;
Published: 13 May 2025.
Edited and reviewed by:
Luisa Lanfrancone, European Institute of Oncology (IEO), ItalyCopyright © 2025 Lu, Ni, Wang, Wang, Jiang and Shang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lei Shang, c2hhbmdsZWlpaWFAMTYzLmNvbQ==; Tao Jiang, amlhbmd0YW9jaGVzdEAxNjMuY29t
†These authors have contributed equally to this work and share first authorship